Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TELK -- Telik, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (695)	8/7/2006 6:41:12 PM
From: zeta1961	Read Replies (1) \| Respond to of 887

. The doublet data which is I think was essentially completely presented, as I recall at Barcelona that data was mature and than we clearly followed these patients for survival and all the others the data was essentially complete when it was presented at Barcelona. Clearly, in the -- and following that we said the data on the Phase II trials reporting ASSIST-3 continuing -- ASSIST-3 and 5 continued strong and we will be publishing that data in the near future and we made that data available clearly for planning purposes to the various organizations under confidentiality which is appropriate we believe. Did we know this?..I didn't..